A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
Status:
RECRUITING
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.